What is the 13F Pro Quality Score for CMPX?

13F Pro ranks Compass Therapeutics, Inc. (CMPX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CMPX's current score at https://13fpro.ai/company/CMPX (free sign-up required for the full ranking).

Where does 13F Pro source CMPX data?

All Compass Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Compass Therapeutics, Inc. files with the SEC under CIK 1738021. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CMPX in?

Compass Therapeutics, Inc. (CMPX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CMPX research updated on 13F Pro?

CMPX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Compass Therapeutics, Inc.(CMPX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1738021 CMPX stock profile & AI dashboard →

13F Pro Quality Score

28.1/100

Rank #2,375 of 2,739 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

3.8/100

Earnings Quality

27.6/100

Free Cash Flow

30.0/100

Institutional Flow

79.2/100

Revenue Scale

30.0/100

Dilution Risk

0.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CMPX Scores 28/100

exact factor attribution · 2026-03-04

CMPX's composite is driven by institutional flow, held back by capital efficiency and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+1.5 pts

79th pct

Earnings growth

-1.0 pts

30th pct

Earnings quality

-2.2 pts

28th pct

Shareholder dilution

-2.5 pts

1th pct

Profitability

-3.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.6 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CMPX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Compass Therapeutics, Inc. (CMPX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CMPX at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,375 of 2,739 stocks — the bottom half of the AI-ranked universe. CMPX scores in the top quartile across institutional flow (79.2). Areas of concern include balance sheet strength (3.8) and earnings quality (27.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Compass Therapeutics, Inc. reports net income of $-25.2M, free cash flow of $-14.9M. Top institutional holders of CMPX by reported 13-F value include TANG CAPITAL MANAGEMENT, ORBIMED ADVISORS, SUVRETTA CAPITAL MANAGEMENT, based on the most recent SEC filings. CMPX trades on the Nasdaq exchange and files with the SEC under CIK 1738021. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CMPX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Compass Therapeutics, Inc. directly from SEC EDGAR. Compass Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 14 and 28 since 2026, currently 28.1 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-25.2M

Free Cash Flow

Q2 2026

$-14.9M

ROIC

Q2 2026

-65.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 —FY23 $0.00FY24 $850.0KFY25 $0.00

Net Income

-34.7% YoY

$-66.5MFY 2025

FY22 $-39.2MFY23 $-42.5MFY24 $-49.4MFY25 $-66.5M

Operating Income

-28.6% YoY

$-72.8MFY 2025

FY22 $-41.7MFY23 $-50.4MFY24 $-56.6MFY25 $-72.8M

Total Assets

+56.4% YoY

$219.6MFY 2025

FY22 $199.6MFY23 $156.9MFY24 $140.4MFY25 $219.6M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-9.6% YoY

$-49.1MFY 2025

FY22 $-34.1MFY23 $-40.6MFY24 $-44.9MFY25 $-49.1M

Free Cash Flow

-9.5% YoY

$-49.2MFY 2025

FY22 $-34.3MFY23 $-40.6MFY24 $-44.9MFY25 $-49.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$850.0K	$0.00	—	—	—
Net Income	$-66.5M -34.7%	$-49.4M -16.2%	$-42.5M -8.3%	$-39.2M +52.3%	$-82.2M -178.6%	$-29.5M
Operating Income	$-72.8M -28.6%	$-56.6M -12.4%	$-50.4M -20.9%	$-41.7M +49.1%	$-81.9M -194.4%	$-27.8M
Total Assets	$219.6M +56.4%	$140.4M -10.5%	$156.9M -21.4%	$199.6M +29.8%	$153.8M +196.2%	$51.9M
Total Debt	—	—	—	—	$0.00 -100.0%	$9.3M
Operating Cash Flow	$-49.1M -9.6%	$-44.9M -10.4%	$-40.6M -19.0%	$-34.1M -73.5%	$-19.7M +26.6%	$-26.8M
Free Cash Flow	$-49.2M -9.5%	$-44.9M -10.5%	$-40.6M -18.4%	$-34.3M -61.7%	$-21.2M +21.1%	$-26.9M

Get alerted when CMPX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Compass Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CMPX

TANG CAPITAL MANAGEMENT LLC
$39.4M17,990,782 sh
ORBIMED ADVISORS LLC
$33.3M15,219,994 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$30.9M14,101,159 sh
BlackRock, Inc.
$24.7M11,281,781 sh
STATE STREET CORP
$21.8M9,953,653 sh
Enavate Sciences GP, LLC
$17.1M7,788,150 sh
Vivo Capital, LLC
$17.0M7,757,060 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.4M6,118,782 sh
Palo Alto Investors LP
$12.8M5,831,813 sh
MILLENNIUM MANAGEMENT LLC
$10.3M4,713,247 sh

Fund	Value	Shares
TANG CAPITAL MANAGEMENT LLC	$39.4M	17,990,782
ORBIMED ADVISORS LLC	$33.3M	15,219,994
SUVRETTA CAPITAL MANAGEMENT, LLC	$30.9M	14,101,159
BlackRock, Inc.	$24.7M	11,281,781
STATE STREET CORP	$21.8M	9,953,653
Enavate Sciences GP, LLC	$17.1M	7,788,150
Vivo Capital, LLC	$17.0M	7,757,060
VANGUARD CAPITAL MANAGEMENT LLC	$13.4M	6,118,782
Palo Alto Investors LP	$12.8M	5,831,813
MILLENNIUM MANAGEMENT LLC	$10.3M	4,713,247

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CMPX on your watchlist

Track score changes the day Compass Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CMPX a good stock to buy?

13F Pro's AI-powered analysis of Compass Therapeutics, Inc. (CMPX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CMPX are available on the CMPX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CMPX is classified as a small company.

Which hedge funds own CMPX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CMPX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Compass Therapeutics, Inc.'s investment landscape.